MedTrace Logo

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

NCT07229729 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-12-01

No results posted yet for this study

Summary

The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.

Conditions

Interventions

DRUG

SHR-A2102

SHR-A2102.

DRUG

Adebrelimab

Adebrelimab.

DRUG

Paclitaxel

Paclitaxel.

DRUG

Carboplatin

Carboplatin.

DRUG

Alomnertinib Mesilate

Alomnertinib Mesilate.

DRUG

Furmonertini Mesilate

Furmonertini Mesilate.

DRUG

Osimertinib Mesylate

Osimertinib Mesylate.

Sponsors & Collaborators

  • Shanghai Hengrui Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-24
Primary Completion
2026-10-31
Completion
2029-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07229729 on ClinicalTrials.gov